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SUMMARY
A multivariate time-series regression model was developed in order to describe the 2005–2008
age-speciﬁc time-course of varicella sentinel surveillance data following the introduction of a
varicella childhood vaccination programme in Germany. This ecological approach allows the
assessment of vaccine eﬀectiveness under ﬁeld conditions by relating vaccine coverage in cohorts
of 24-month-old children to the mean number of cases per reporting unit in the sentinel network.
For the 1–2 years age group, which is directly aﬀected by the vaccination programme, a one-dose
vaccine eﬀectiveness of 83.2% (95% CI 80.2–85.7) was estimated which corresponds to previous
approaches assessing varicella vaccine eﬀectiveness in the ﬁeld in the USA.
Key words: GP surveillance systems, infectious disease epidemiology, statistics, vaccines,
varicella zoster.
INTRODUCTION
Varicella vaccination programmes have been im-
plemented in several countries during the last decade
[1–4]. Evaluations of the varicella vaccination pro-
gramme in the USA have demonstrated an impressive
eﬀect with respect to varicella-related mortality [1],
hospitalization [2, 3] and incidence [4], despite
limited vaccine eﬃcacy of one dose [5] and even
two doses of varicella vaccine [6, 7]. However, the
epidemiological characteristics for the spread of var-
icella in unvaccinated populations vary considerably
[8] making assessment of the eﬀects of vaccination
programmes on a national level mandatory.
Since varicella is very common in early childhood
[9] assessment of the incidence of temporal trends of
varicella incidence at a national level is not feasible.
Therefore trends are either monitored regarding
incidence in regional samples [1, 8] or in sentinel
surveys [10]. While trends in case ascertainment can
be depicted by these approaches, quantifying vaccine
eﬀects and age-group interdependencies may require a
more sophisticated approach. We therefore attempted
to model the time-course of varicella following the
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introduction of a universal childhood vaccination
programme in Germany in 2004 [10] targeted at
children aged 1–2 years and sought to apply these
analyses to an ecological approach in order to assess
varicella vaccine eﬀectiveness.
Measuring the success of an immunization pro-
gramme under ﬁeld conditions is a particular chal-
lenge which can be addressed by epidemiological
means. The study of vaccine eﬀectiveness typically
investigates direct eﬀects in individuals using diﬀerent
vaccination models and study designs [11]. However,
the literature on quantifying population eﬀects of
vaccination is less developed and typically occurs
within the framework of a detailed dynamic model
for disease transmission (see e.g. [12, 13] for such
an approach in the context of varicella vaccination).
However, for data originating from routine monitor-
ing such models are too detailed. The screening
method [14] is one approach operating under such
monitoring conditions, but it requires knowledge
about both the vaccination status of cases and the
proportion of population vaccinated, which are not
always available. Furthermore, the approach does not
speciﬁcally address the time-varying aspect of cover-
age following the introduction of a vaccination pro-
gramme. Our selected ecological approach provides a
solution for estimating population-level eﬀects of
vaccination under ﬁeld conditions by using a coarse
disease transmission model based on time-series
methodology which indirectly takes herd immunity
eﬀects into account. Classical time-series modelling
has already received some attention in analysing vac-
cine eﬀects in populations [15–19]. However, previous
analyses are typically restricted to univariate analyses
with information on vaccination coverage entered
only in binary form. Our approach continues along
these lines and is novel in as much as it considers
coverage percentage as an exogenous time series and,
being a multivariate time-series model, handles pro-
gression in diﬀerent age strata.
Given the above, our research question can be
formulated as follows: does modelling the time-course
of varicella following the introduction of the varicella
vaccination programme in Germany allow for
quantiﬁcation of age-speciﬁc eﬀects and for an eco-
logical assessment of vaccine eﬀectiveness? Speciﬁ-
cally, we wanted to quantify direct vaccine eﬀects in
the vaccinated 1–2 years age group by using seasonal
and autoregressive terms in the model as proxy for
adjusting for indirect vaccine eﬀects in all regarded age
groups.
METHODS
Data sources
A convenience sample of 1176 primary-care phys-
icians, consisting of 57% paediatricians and 43%
general practitioners (GPs) which accounted for
about 15% of all German paediatricians and about
1% of all German GPs in private practice was the
sampling frame for the sentinel network. Sentinel
network physicians of both groups are distributed in
German federal states in the same proportion as the
total number of respective physicians in private prac-
tice. Physicians reported aggregated monthly num-
bers of varicella cases by age group. Clear case
deﬁnitions for reporting were provided. A case of
varicella is deﬁned as a person presenting with a
clinical picture compatible with varicella, i.e. the
presence of skin exanthema and concomitant presen-
tation of papules, blisters, pustules, crusts [10]. Zero-
reporting and active reminders were included, but as
physicians participated voluntarily without any in-
centives for their reports, the additional workload for
them needed be kept as low as possible. Hence, vac-
cination status of cases was not recorded and only
aggregated case numbers by age groups were re-
ported. Furthermore, as patients are free to choose
and change their physician and only a sample of
physicians report to the sentinel network, the popu-
lation size under surveillance can not be deﬁned [10].
Vaccine uptake was extrapolated from health in-
surance data in one [Schleswig-Holstein (SH)] of the
16 German federal states. Vaccination billing for
about 90% of all children in Germany is handled by
the Association of Statutory Health Insurance
Physicians (‘Kassena¨rztliche Vereinigungen’) in the
diﬀerent German federal states [20]. Children in the
health insurance system were traced from birth to age
24 months upon billing for the well-baby check visits.
Varicella vaccination status by age 24 months was
assessed for consecutive birth cohorts from 2003 to
2006 and this constituted the numerator for assessing
vaccination coverage for the diﬀerent birth cohorts.
Analyses
Data from all paediatricians and GPs participating in
the sentinel network were used in the analysis. As re-
sponse for the time-series modelling we chose the
monthly ‘mean number of varicella cases per report-
ing unit ’. This quantity accounts for the varying
number of reporting units in the sentinel network,
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whereas the size of the reporting units is considered to
be stable over time. The dynamics of the response
variable over time is described by a two-phase model :
at the ﬁrst level the mean number of varicella cases at
time t (measured in months) per sentinel reporting
unit was modelled. This was done using a linear pre-
dictor with intercept, linear trend, seasonal terms and
an additional ARMA(p,q) model with p auto-
regressive (AR) and q moving-average (MA) terms.
At the second level the age distribution of the ob-
served cases at time t in the<1, 1–2, 3–4, 5–9 and>9
years age groups was handled by a multinomial
logistic regression model (for further details on the
modelling see the Appendix). For levels 1 and 2,
Akaike’s Information Criterion (AIC) was used to
select from a set of candidate models. A strong cor-
relation between vaccination coverage and time
(measured in months) was expected. Including both
month and vaccination coverage as covariables would
thus lead to strong collinearity and hence lead to
stability problems if they are both included. There-
fore, the following strategy was applied: ﬁt separate
models including either month or coverage as covari-
ate and use AIC to select the better model.
We used R [21] – a free software environment for
statistical computing and graphics – to perform all
statistical computations.
In order to estimate vaccination coverage nation-
ally, coverage estimates for SH were extrapolated
to the whole of Germany as follows. For each of the
16 federal states the SH time-series was shifted in
time such that the time of reimbursement in SH
(August 2005) was moved to the corresponding
month of reimbursement in the federal state. The
resulting 16 time series were then averaged by
weighting with the number of sentinel network units
for the respective federal state in that month.
Vaccine eﬀectiveness is conventionally deﬁned as
the reduction between the risk of unvaccinated and
vaccinated individuals divided by the risk of unvac-
cinated individuals [22], i.e. 1minus the relative risk. In
our model we use a before-and-after approach to esti-
mate vaccine eﬀectiveness under ﬁeld conditions. We
consider 0% coverage as baseline – representing the
unvaccinated situation – and compare this with 100%
coverage, corresponding to the vaccinated situation.
Using this approach, vaccine eﬀectiveness can be esti-
mated in the unstratiﬁed situation as 1 minus the
relative reduction in the expectation of the response,
i.e. 1 – m100% coverage/m0% coverage=1 – exp(b1)100, where
b1 represents the eﬀect of coverage in the level 1 model
described in the Appendix. Since coverage is only
available for the 1–2 years age group, we obtained
an estimate of vaccine eﬀectiveness for this speciﬁc
age group by computing the relative reduction in ex-
pectation for this age group, i.e. 1 – m100% coverage,1–2 yr/
m0% coverage,1–2 yr (see Appendix for details on how
these expectations are obtained by a combination of
level 1 and level 2 models).
RESULTS
Figure 1 shows the monthly vaccination coverage
among the 24-month-old birth cohort in SH. Here,
reimbursement started in August 2005. Also shown in
Figure 1 is our extrapolated national coverage time-
series ; the extrapolated coverage percentage at the
beginning of the sentinel network in April 2005 was
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Fig. 1. Vaccination coverage in the 24-month-old birth cohort in Schleswig-Holstein (SH) and the extrapolated coverage
for Germany.
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11%. The corresponding coverages were 38%, 63%,
78%, respectively, at 1, 2 and 3 years after the sentinel
network started. A rough comparison (not shown)
with diﬀerently collected yearly coverage rates for the
24-month-olds from the 2004 and 2005 birth cohorts
in an available subset of ten federal states showed that
our extrapolation provided a fair description of the
coverage of these two cohorts.
The mean number of monthly reporting units in
the sentinel network for the available 42 months of
monitoring was 679 (S.D.=41). Figure 2 shows the
observed monthly time series of mean number of
cases per reporting unit together with the ﬁt of our
level 1 model containing intercept, trend and periodic
function, f(t), consisting of two harmonics with
frequencies of 12 and 6 months, respectively. An
ARMA(2,1) model captured the remaining auto-
correlation of the error terms. This level 1 model was
determined as the best-ﬁtting model according to AIC
in the investigated set of candidate models. The esti-
mated coeﬃcient for the time trend in this model
is x0.023 (95% CI x0.025 to x0.020), i.e. the re-
duction in the mean number of cases per reporting
unit is signiﬁcant (P<0.001) and corresponds to a
decrease in the mean number of cases per reporting
unit by a factor of exp(x0.023)=0.978 per month or
exp(x0.023r12)=0.762 per year.
Figure 3 shows the model-ﬁtted values combining
level 1 and level 2 models (using month as linear
covariate). Also shown are the estimated time trends,
mt,i, for each of the ﬁve age groups (<1, 1–2, 3–4, 5–9,
>9 years) as described in the Appendix.
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Fig. 2. Observed and model-ﬁtted mean number of varicella cases per reporting unit in the sentinel network.
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Fig. 3. Two-level model-ﬁtted mean number of cases for each of the ﬁve age groups. Also shown are the trends mt,i
(smooth lines) for each age group i and time-point t obtained by combining the intercept and trend components of the level 1
and level 2 models.
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A decline in all ﬁve age groups was observed.
For better interpretation, Table 1 shows the model-
predicted yearly relative reductions for the ﬁrst three
full years of the sentinel network. As expected, the
highest decline is observed in the 1–2 years age group,
but all other age groups also experienced a decline.
For example, the percentage reduction over 3 years in
the <1 year age group is given by 1x0.77r0.76r
0.76=56%. The corresponding reductions in the
other groups were 69%, 62%, 42% and 30%. Since
no vaccinations were performed in the <1 year age
group, the reduction here may be entirely due to herd
eﬀect.
However, the extrapolated national vaccination
coverage percentage shown in Figure 1 has a Pearson
correlation coeﬃcient with month of 0.97. Using
either month or coverage percentage in the model
shows that the model with the covariate coverage
provides the better ﬁt (AIC of x44.66 vs. x39.73).
When replacing the term b1t with b1(coverage in %) in
the level 1 model, the estimated coeﬃcient of coverage
isx0.013 (95% CIx0.014 tox0.011), which means
that the coverage eﬀect is signiﬁcant (P<0.001) and
for each percentage point of vaccination coverage in
the 24-month-old cohort the mean number of cases
per reporting unit is reduced by a factor of 0.987.
While this approach describes the overall impact of
the vaccination programme, the assessment of vaccine
eﬀectiveness requires conﬁning the analysis to vacci-
nated age groups only.
To speciﬁcally target the reduction in the 1–2 years
age group, for whom the vaccine uptake could be es-
timated and who experience the direct vaccine eﬀects,
we combined the above ﬁndings with the level 2 model
where the linear time trend is also replaced with
coverage, i.e. coverage is used as single linear covari-
ate in both level 1 and level 2 models, but the har-
monic functions at both levels remain functions of
time. This allows us to predict the reduction factor
such as m100%,1–2 yr/m0%,1–2 yr for the 1–2 years age
group, i.e. the reduction of a hypothetical 100%
vaccination coverage in the 24-month-old birth co-
hort compared to a coverage baseline of 0%. This
comparison mimics the conventional vaccine eﬀec-
tiveness assessment comparing attack rates in vacci-
nated and unvaccinated individuals. Table 2 gives the
results for coverage percentages between 60% and
100%. This yields a vaccine eﬀectiveness of 83.2%
(95% CI 80.2–85.7) in the 1–2 years age group.
DISCUSSION
Since the implementation of most vaccination pro-
grammes is progressive with gradual increments of
vaccination coverage, the decrease of the targeted
diseases due to direct and indirect vaccine eﬀects will
also be progressive. During the implementation of a
universal varicella childhood vaccination programme
in Germany we demonstrated that modelling of the
time-course of disease allows estimation of the re-
duction for diﬀerent age groups for comparison of
direct and indirect vaccination eﬀects. With further
inclusion of vaccine uptake, an ecological estimate for
vaccine eﬀectiveness was possible and yielded almost
identical results to other varicella vaccine eﬀectiveness
estimates.
Although year-to-year variation in the incidence of
varicella (measured by GP visits or hospitalizations)
has been reported from various countries and settings,
the predicted and observed decline of varicella cases
in the German sentinel network system, mainly in
the 1–2 years age group, is consistent with an eﬀect
of vaccination rather than a secular trend. Given
the short time-span of the monitoring period it
appears unlikely that the reduction is attributable
to secular changes in factors other than vaccine use
[19]. Other epidemiological investigations and mod-
elling approaches [23–26] also indicate a lack of large
Table 1. Model-predicted relative reduction factors
for each of the ﬁve age groups
Ratio
Age group (years)
<1 1–2 3–4 5–9 >9
m13,i/m1,i 0.77 0.68 0.73 0.84 0.89
m25,i/m13,i 0.76 0.68 0.72 0.84 0.89
m37,i/m25,i 0.76 0.67 0.72 0.83 0.88
Table 2. Model-predicted reduction factors for ﬁve
hypothetical coverage percentages
Coverage
Predicted reduction factor
mcoverage %,1–2 yr/m0%,1–2 yr 95% CI
60% 0.349 0.317–0.384
70% 0.291 0.260–0.326
80% 0.243 0.214–0.277
90% 0.202 0.175–0.235
100% 0.168 0.143–0.198
CI, Conﬁdence interval.
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multi-year periodicities. However, our approach re-
mains sensitive to unexplained trends in incidence,
whereas ordinary year-to-year ﬂuctuations are taken
into account by the stochastic nature of the model.
Early detection of a herd immunity eﬀect in chil-
dren aged <1 year and the ﬁnding of similar vaccine
eﬀectiveness estimates for the ecological compared to
other approaches are important ﬁndings with respect
to varicella vaccination programmes.
Impressive herd immunity eﬀects of varicella vac-
cination programmes have previously been shown in
adults, e.g. a reduction of 74% over a 10-year period
with increasing childhood vaccination coverage in the
USA [27]. Even more impressive reductions than in
adults or adolescents have been reported in infants
too young to be immunized themselves [1, 15, 16].
These impressive indirect eﬀects were achieved over a
6-year period with>90% coverage since programme
implementation [28] and over 10 years with vacci-
nation coverage >80% achieved after the ﬁfth year
[29]. Our results show, that even with coverage<80%
ﬁrst eﬀects of indirect protection might occur.
Scientiﬁcally more relevant, however, might be the
suggested ecological approach to estimate vaccine ef-
fectiveness based on time-series methodology. Using
vaccine uptake in the model instead of time to esti-
mate the reduction of reported varicella cases per in-
crement in vaccine uptake appears justiﬁed because
the model ﬁt for vaccine uptake was considerably
better than the ﬁt for year of observation. A hypo-
thetical vaccine uptake of 100% would reﬂect the ef-
fectiveness of the vaccine in vaccinated individuals.
Vaccination status at age 24 months was used as an
estimate for the 1–2 years age group, which covers
children aged 12–35 months. We expected that
choosing coverage at the midpoint of the age group
balances between lower and higher coverage rates in
children aged 12–23 and 24–35 months. The reduction
of the reported varicella cases for each 1% increment
in vaccination coverage was used to estimate vaccine
eﬀectiveness from an ecological approach. As the
time-series model contains autoregressive terms, herd
immunity eﬀects are indirectly addressed in the mod-
elling. A decrease in the mean number of cases (and
hence the infection pressure) during previous months
implies a smaller contribution from the past for the
current response.
Estimates of varicella vaccine eﬀectiveness vary
depending on the setting of the assessment [30], sev-
erity of the infection [5], number of vaccine doses [6]
and duration of follow-up [31]. Most of these were
based on outbreak investigations [30, 32], a cohort
study [33] a household contact study [34] or a case-
control study [35]. The median eﬀectiveness has been
estimated at 72% and 71% [30, 32] for all and 96.5%
or 89% [5, 30], respectively, for moderate to severe
infections fromoutbreak investigations.The respective
ﬁgures were 83% and 100% in a prospective cohort
study [33], 85% and 97% in a case-control study con-
ﬁned to laboratory-conﬁrmed cases [35] and 79% and
92% in a household contact study for moderate cases
[34]. The German varicella childhood vaccination
programme was initiated with one-dose varicella vac-
cination and only recently switched to a two-dose
schedule in 2009. The observed vaccine eﬀectiveness
of 83.2% in our ecological approach is close to the
estimates from outbreaks in the USA which similarly
included all levels of severity of varicella.
Vaccination uptake was only assessed in one
German federal state; however, vaccination coverage
measured for children at school entry is similar in SH
to that in Germany on average [36]. The challenge in
estimating vaccination coverage from health in-
surance data, which provide complete information on
all vaccines given, is the generation of an appropriate
denominator [20]. The approach to include children
with follow-up information up to age 24 months al-
lows deﬁning of a valid denominator. Almost 90% of
children have completed all well-baby check-up visits
scheduled within the ﬁrst 2 years of life. If children
without complete well-baby check-up visits were less
completely vaccinated, this would account for an
overestimation of the vaccination coverage by a
maximum of 10%. However, formal assessment of
this ﬁgure in SH, found an overestimation of only 1%
[37]. As a sensitivity analysis incorporating uncer-
tainty from well-baby check-ups and the extra-
polation to other federal states we investigated the
following: if using 90% of the coverage rate observed
in Figure 1 as covariate, the resulting estimate for
vaccine eﬀectiveness would be 86.3%. As a conse-
quence, our reported ﬁgure of 83.2% is conservative
with respect to potential overestimation of coverage.
Our time-series modelling makes up an easy to im-
plement alternative to assessing vaccine eﬀectiveness.
The similarity of our ecological estimate of varicella
vaccine eﬃcacy compared to other approaches can be
explained by absence of secular trends and consistent
reporting. Lack of large multi-year periodicities is
suggested from other epidemiological investigations
and modelling approaches [29, 34–36]. Furthermore,
there was no speciﬁc varicella catch-up vaccination
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programme in Germany. Even though vaccinations
have occurred in the 3–4, 5–9 and >9 years age
groups due to delay between recommended and actual
vaccination age [20], the eﬀects can be considered as
minor. Finally, ascertainment of cases and vacci-
nation coverage was consistent over time due to the
structure of the reporting instruments.
A limitation of the current modelling is that cover-
age percentage enters the predictor of the log-linear
model in linear form. Predictions about the eﬀect of
hypothetical 100% coverage are sensitive to this as-
sumed parametric form. An alternative could be to
use more ﬂexible functional forms based on semi-
parametric penalized spline approaches [38], but in
our case such modelling did not indicate strong de-
viations from the linear form. Furthermore, the
multinomial phase 2 model implies a ﬁxed variance-
covariance structure of the count data series,
which – similar to binomial time series – might be
subject to overdispersion [39]. An alternative model-
ling approach based on a multivariate AR(1) Poisson
model with population oﬀsets can be found in Herzog
et al. [40]. However, their model does not speciﬁcally
address the sentinel network situation found in our
context and is less ﬂexible with respect to the auto-
regressive modelling.
It should be noted that standard epidemic models
suggest that the number of new cases is proportional
to the product of the proportions being infectious
and susceptible. Thus, our use of infection pressure
in the autoregression represents a pragmatic ap-
proximation when no information about the suscep-
tible proportion is available. Theoretically, changes in
the susceptible proportions due to vaccination could
be reﬂected by a time-varying autoregression par-
ameter. Furthermore, as herd eﬀects are reﬂected
in the unstratiﬁed level 1 model, we implicitly assume
that these eﬀects are homogeneous over all age
groups.
Finally, given the short period of the German vac-
cination programme, our analyses of vaccine eﬀec-
tiveness do not take into account that immunity from
vaccination might wane over time which would con-
found our eﬀectiveness estimate. Re-assessment of
waning immunity might become necessary, once the
programme has been in operation for a longer time.
Altogether, our vaccine eﬀectiveness estimates cor-
respond to immediate eﬀects and thus do not reﬂect
long-term impact. It is well known that vaccination
eﬀects can be exaggerated during the initial period of
a vaccination programme, e.g. due to ‘honeymoon
eﬀects ’ [41] or boosting from natural varicella cases
which is expected to decline in the future [42]. Hence
our estimates may not be directly comparable with
eﬀectiveness based on individual-level data since they
are subject to transient herd eﬀects. However, the
proposed two-phase multivariate time-series model-
ling represents a novel view on investigating popu-
lation-level vaccine eﬀectiveness for an age-stratiﬁed
population indirectly taking current herd eﬀects into
account. With this model, the dynamics using a
monthly time resolution were investigated and quan-
tiﬁed. Such modelling is especially helpful in case
of short time-series when starting monitoring im-
munization programmes without available pre-
vaccination data.
APPENDIX
Statistical methodology
Allow nt to be the number of sentinel network re-
porting units at time t ; ct the total number of reported
varicella cases at this time and (ct,<1, ct,1–2, ct,3–4, ct,5–9,
ct,>9)
T a column vector of length 5 containing the
number of cases in each of the ﬁve age groups. The
elements of this vector sum to ct. At the ﬁrst level, our
interest is in modelling the response yt=ct/nt, i.e. a
random variable reﬂecting the mean number of cases
per reporting unit at time t. To reﬂect the fact that the
response is non-negative, we transform the response
using the natural logarithm and hence model log(yt).
Now, a time-series model is used to model trend and
seasonality:
log (yt)=b0+b1t+f(t)+et,
where t=1, 2, … , 42 reﬂects time (in months) and et is
possibly correlated zero mean Gaussian random vari-
ables with variance s2. Because a log-transformation
is used, all eﬀects should be interpreted in multi-
plicative fashion, i.e. exp(b0) corresponds to the base
level and exp(b1) is the factor multiplied on this base
level for each additional month. Furthermore, f(t) is
a periodical function with period 12 months, e.g.
f(1)=f(13). The function f(t) is obtained by combining
several sine and cosine terms with diﬀerent fre-
quencies. An advantage of the above regression for-
mulation is that additional covariates can be easily be
added to the model.
The expectation of the response can be calculated as
mt=E(yt)= exp b0+b1t+f(t)+1=2s
2
 
:
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When using, e.g. vaccination coverage instead of time
as linear covariate, vaccine eﬀectiveness is deﬁned as
1 – m100% coverage/m0% coverage=1 – exp(b1)100.
Since our data are of time-series nature, we ex-
pected the observations yt to be correlated. Even after
modelling trend and seasonality as explained above,
we expected remaining correlation to be present
within the series. If this additional correlation (i.e.
autocorrelation) is not taken into account, the stan-
dard errors obtained from the modelling would be too
optimistic and hence wrong results about signiﬁcance
will be obtained. To capture this autocorrelation, a
ARMA(p,q) model with p autoregressive (AR) and q
moving-average (MA) terms is ﬁtted to the residuals,
et. This modelling approach is a well-known pro-
cedure from time-series analysis for ﬁtting seasonal
time-series data [43].
Estimation of the model parameters b0, b1, s
2, the
parameters of f(t) and the coeﬃcients in the seasonal
ARMA model given known values of p,q was per-
formed by standard likelihood methods. The appro-
priate parameters p,q of the ARMA(p,q) time-series
model were selected according to AIC in all nine
models with p,q being either 0, 1 or 2. We also in-
vestigated seasonal ARMA(p,q) models, but as the
seasonality is modelled explicitly using f(t), no such
additional complexity improved the AIC.
The age-speciﬁc dynamics in the mean number of
cases per reporting unit is modelled by a two-stage
approach. First, the above presented seasonal ARMA
model captures the development in the mean number
of visits per reporting unit over all age groups.
Second, the vector of proportions (pt,<1, pt,1–2, pt,3–4,
pt,5–9, pt,>9)
T in age groups at a speciﬁc time-point
is modelled by multinomial logistic regression using
category-speciﬁc intercept, trend and period function
(see e.g. [39]). Altogether,
Level 1:
yt=
ct
nt
= exp (b0+b1t+f(t)+et),
et  ARMA(p, q;s2),
Level 2:
(ct,<1, ct, 1x2, ct, 3x4, ct, 5x9, ct,>9)
T
 Multinom(ct, (pt,<1, pt, 1x2, pt, 3x4, pt, 5x9, pt,>9)T):
When estimating parameters at level 2 we used the
actual observed ct and not the level 1 predicted ct –
this makes it possible to ﬁt the two models indepen-
dently from each other. However, for the later pre-
dictions we combined level 1 and level 2 models
using the multiplication ytr(pt,<1, pt,1–2, pt,3–4, pt,5–9,
pt,>9)
T, where yt is now the predicted value from level
1 and the vector of probabilities is the prediction from
level 2. With this combination a time-series model for
the mean number of cases per sentinel unit in each age
group is obtained. We now calculate
mt, i=E(yt, i)
=
exp c0, i+b0+(c1, i+b1)  t+f(t)+fi(t)+ 12 s2
 
P
j2{<1, 1x2, 3x4, 5x9,>9}
exp(c0, j+c1, jt+fj(t))
,
for i=<1, 1–2, 3–4, 5–9, >9, with the b values and
the c values being the intercept and trend parameters
in the level 1 and level 2 models, respectively, f(t) and
fi(t) being the harmonic functions, and s
2 being the
variance of the level 1 model error term. Note that for
the reference age group (e.g. 1–2 years), the restric-
tions c0,1–2=c1,1–2=0 and f1–2(t)=0 for all t applies,
i.e. no parameters need to be estimated for this group.
A big advantage of our proposed multivariate two-
phase model, compared to modelling the mean num-
ber of varicella cases separately for each age group, is
that it takes into account, that the number of cases
summed over the age groups equals the observed
total number of cases. However, when considering
the dynamics within a single age group in our model,
the interpretation of the model parameters is not
straightforward. Instead, we report ratios such as
m13,i/m1,i giving the relative reduction within the ﬁrst
year of the sentinel network for a speciﬁc age
group. Conﬁdence intervals for these reduction
factors can be obtained by parametric bootstrap
exploiting the asymptotic normality of both the b
values and the c values in the computation of the re-
spective mt,i values. When using vaccination coverage
as linear covariate instead of time, the relative re-
duction m100% coverage,i/m0% coverage,i denotes the rela-
tive reduction in the expectation of the response in age
group i – by comparing the 0% coverage with the
100% coverage situation. Again, this can be used to
deﬁne vaccine eﬀectiveness. In case the harmonic
functions of time remain in the predictors of the
level 1 and level 2 models, one would typically ﬁx
time to some arbitrary value, e.g. t=0, for the
comparison.
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